IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
Status:
Terminated
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying mitotane and IMC-A12 to see how well they work
compared with mitotane alone in treating patients with recurrent, metastatic, or primary
adrenocortical cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as
mitotane, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Monoclonal antibodies, such as IMC-A12, can block
tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
Others find tumor cells and help kill them or carry tumor-killing substances to them. It is
not yet known whether mitotane is more effective with or without monoclonal antibody IMC-A12
in treating adrenocortical cancer.